Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Investigational New Drugs · 2025
DOI: 10.1007/s10637-024-01490-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Saisai Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Pyrimidines, Pyrazoles, Antineoplastic Agents. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Natural Science Foundation of Shanxi Province, Jilin Scientific and Technological Development Program, Jilin Tianhua Health Charity Foundation.
Abstract (Originalsprache)
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatment of prostate cancer, and it is urgent to explore an innovative therapeutic strategy. MK-1775, a highly selective WEE1 inhibitor, is shown to have favorable therapeutic benefits in several solid tumor models. Recent evidence suggests that the combination of MK-1775 with DNA-damaging agents could lead to enhanced antitumor efficacy. Here, our results demonstrate that MK-1775 alone could indeed inhibit proliferation and induce apoptosis in prostate cancer. Moreover, the combination of MK-1775 and a dual PI3K and HDAC inhibitor, CUDC-907, can synergistically inhibit cell proliferation and dramatically induces apoptosis in prostate cancer cells. This effect is partially mediated by DNA damage, resulting from the downregulation of DNA damage response (DDR) proteins such as CDK, CHK, and RRM1/2. Notably, the combination of MK-1775 and CUDC-907 leads to significant antitumor effects in vivo. Our findings provide a strong basis for a promising combination strategy against prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Jilin University, Changchun, China.
- National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, China.
- Departments of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA, USA.
- College of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China.
- Department of Urology, The First Hospital of Jilin University, Jilin University, Changchun, China. lu_ji@jlu.edu.cn.
- The First Hospital of Jilin University, Jilin University, Changchun, China. lu_ji@jlu.edu.cn.
Förderung
- Natural Science Foundation of Shanxi Province
- Jilin Scientific and Technological Development Program
- Jilin Tianhua Health Charity Foundation
Zitieren
APA
Ma, S., Xu, Y., Liu, M., Wu, S., Zhang, Y., Xia, H., Lu, J., & Zhan, Y. (2025). Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01490-8
Vancouver
Ma S, Xu Y, Liu M, Wu S, Zhang Y, Xia H, et al. Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer. Investigational New Drugs. 2025. doi:10.1007/s10637-024-01490-8
BibTeX
@article{Ma2025,
author = {Ma, Saisai and Xu, Yichen and Liu, Minmin and Wu, Shuaida and Zhang, Ye and Xia, Hongyan and Lu, Ji and Zhan, Yang},
title = {Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer},
journal = {Investigational New Drugs},
year = {2025},
doi = {10.1007/s10637-024-01490-8}
}
EUVIMED